XEN Gel Stent Implantation in Eyes With Previous Glaucoma Filtering Surgeries: A Case Series
Open Access
- 19 December 2022
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32741
Abstract
In this study, we aimed to analyze the efficacy and safety of ab interno XEN® gel stent (Allergan Inc., Dublin, Ireland) implantation in a series of eyes with open-angle glaucoma and a history of previous filtering glaucoma surgeries. This retrospective, single-center study included all eyes that underwent XEN gel implantation with a minimum follow-up of 18 months that had previously undergone a filtering glaucoma surgery. The main outcomes were intraocular pressure (IOP) variation (baseline, first day, first week, and first, third, sixth, 12th, and 18th months), the number of hypotensive eyedrops at 18 months, intraoperative and postsurgical complications, and the need for subsequent glaucoma surgery. A total of 10 eyes from nine patients were enrolled in the study. IOP significantly decreased from 24.0 ± 2.4 mmHg to 7.8 ± 1.6 mmHg on the first day, 9.4 ± 2.2 mmHg in the first week, and 12.3 ± 4.8 mmHg, 14.7 ± 4.3 mmHg, 13.3 ± 3.8 mmHg, 11.7 ± 1.9 mmHg, and 12.3 ± 1.9 at the first, third, sixth, 12th, and 18th month, respectively (p < 0.001), with a 49.5% reduction in IOP at the end of the follow-up. The number of hypotensive eyedrops decreased significantly from 3.5 ± 0.5 (3-4) to 0.7 ± 0.7 (0-2) (p = 0.026). No intraoperative or postsurgical complications were recorded. In total, seven (70%) eyes achieved controlled IOP of <18 mmHg without any anti-glaucomatous medications, and one (10%) eye with the use of topical prostaglandin. One (10%) eye was submitted to a surgical revision, and another needed an additional glaucoma surgery during follow-up, with appropriate IOP control at the last follow-up. This case series aims to highlight that the XEN implant can be an option in eyes with IOP levels in the low 20s and previously failed filtering surgeries, with satisfactory efficacy and high safety.Keywords
This publication has 18 references indexed in Scilit:
- Cataract and glaucoma combined surgery: XEN® gel stent versus nonpenetrating deep sclerectomy, a pilot studyBMC Ophthalmology, 2020
- XEN® Gel Stent in Medically Refractory Open-Angle Glaucoma: Results and Observations After One Year of Use in the United StatesOphthalmology and Therapy, 2019
- XEN® Gel Stent for management of chronic open angle glaucoma: A review of the literatureJournal Français d'Ophtalmologie, 2019
- A Retrospective Study of 199 Xen45 Stent Implantations From 2014 to 2016Journal of Glaucoma, 2019
- A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgeryEye, 2018
- Efficacy and Safety of the Ab-interno Xen Gel Stent After Failed TrabeculectomyJournal of Glaucoma, 2018
- Case Report: Xen Ab Interno Gel Stent Use in a Refractory Glaucoma Patient With Previous Filtration SurgeriesJournal of Glaucoma, 2018
- Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysisPLOS ONE, 2017
- Treatment Outcomes in the Tube Versus Trabeculectomy (TVT) Study After Five Years of Follow-upAmerican Journal of Ophthalmology, 2012
- Long-term Outcomes of Repeat vs Initial Trabeculectomy in Open-Angle GlaucomaAmerican Journal of Ophthalmology, 2009